期刊文献+

我国药物经济学应用热点探讨 被引量:3

Hot Spot of Pharmacoeconomics Research and Application in China
原文传递
导出
摘要 目的:促进我国药物经济学应用发展。方法:采用文献分析法,梳理和探讨我国药物经济学应用的热点领域。结果与结论:当前我国药物经济学应用热点领域包括:以价值为基础的药品定价,促进药品创新,保障有效药物的可及性和效果;开展预算影响分析,从预算持有者的角度出发,关注药品服务变化、预算影响及经济可承担性;从决策者角度发挥药物经济学作用。药物经济学基于研究成果数量及其整合能力,能够在宏观、中观、微观多层次政策决策时提供循证支持。 OBJECTIVE: To promote the development of pharmacoeconomics application in China. METHODS: Using litera- ture analysis, hot spots of pharmacoeconomics research and application were summarized and explored in China. RESULT&CON- CLUSIONS: Hot spot of pharmacoeconomics research and application included: value-based drug pricing can promote drug innova- tion and protect the availability and efficacy of effective drugs; budget impact analysis, which is from the view of budget holders. focuses on changes in pharmaceutical services, budget impact and the economy affordability; use pharmacoeconomics from the view of policy makers. Pharmacoeconomics is able to integrate evidence-based supports as the multi-level policy decisions based on the number of research results and ability.
出处 《中国药房》 CAS CSCD 2012年第38期3553-3555,共3页 China Pharmacy
关键词 药物经济学 药品定价 预算影响分析 政府决策 Pharmacoeconomics: Drug pricing Budget impact analysis Policy decision
  • 相关文献

参考文献11

二级参考文献35

  • 1吴晶,孙利华,刘国恩.中国药物经济学学科发展现状[J].中国药物经济学,2008,0(6):29-36. 被引量:13
  • 2王施益,李洪超.对我国高校药物经济学教育开展情况的调查[J].中国药物经济学,2008,3(4):49-61. 被引量:11
  • 3张钧,郭震洲,王立强,任守英.药物经济学概述及在我国运用的几点设想[J].中国药房,1993,4(5):11-13. 被引量:94
  • 4[1]Chambers M. Budget impact analysis for health technology appraisal: P development and application with the NICE appraisal process[J]. Journal of Clinical Ex- cellence, 2002, 4: 203.
  • 5[2]Trueman P. Developing guidance for budget impact an- alysis[J]. Pharmacoeconomics, 2001, 19(6): 609.
  • 6[3]Nuijten M, Rutten F. Combining a budetary- impact analysis and a cost- effectiveness analysis using decision- analytic modelling techniques[J]. Pharmacoecon- omics, 2002, 20(12): 855.
  • 7[4]Detoirnay B, Pribil C. Budget impact model for determ- ining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France[J]. Eur J Health Econom, 2002, 3: 149.
  • 8[5]Simpson KN. Five- Year Budget Impact and Lifetime Cost- Effeciveness of a Lopinavir/Ritonavir (LPV/r)vs. Nelfinavir(NFV) Cpntaining Regimen for Tr- eatment- Naive Patients[P]. International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress, Rotterdam, The Netherlands, 2002.
  • 9JOSEPH L, MICHAEL D, DENNIS F, et al. Retaining and en- hancing the QALY [ J ]. Value Health, 2009, 12 ( sup 1 ) : 1-4, 18 -26.
  • 10HUFFORD M. Methodological advances in the assessment of quali- ty of life in clinical trials [J]. Value Health, 2008, 4(;2) : 181-182.

共引文献46

同被引文献29

引证文献3

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部